Role of cathepsin B in regulating migration and invasion of fibroblast-like synoviocytes into inflamed tissue from patients with rheumatoid arthritis

Cathepsin B (CB), an important proteinase that participates in joint destruction in rheumatoid arthritis (RA), exhibits higher expression in fibroblast-like synoviocyte (FLS) of abnormal proliferative synovial tissues. Whether and how it affects the biological behaviours of RA-FLS, such as migration and invasion, are poorly understood. In the present study, CB expression in synovial tissues of patients with RA and ostearthritis (OA) were measured by quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC), respectively. Stable depletion of endogenous CB was achieved by small interfering RNA (siRNA) transfection, and decrease of CB activity was acquired by using its specific inhibitor (CA074Me). The effects of CA074Me and RNA interference (RNAi) treatments on proliferation, migration, invasion, matrix metalloproteinase (MMP)-2/-9 expression, focal adhesion kinase (FAK) activation, and mitogen-activated protein kinases (MAPKs) phosphorylation of FLS were analysed. In RA synovial tissues, CB was expressed at elevated levels compared with OA synovial tissues. CA074Me could inhibit invasion of FLS obtained from RA patients in an ex-vivo invasion model. CA074Me and siRNA treatments suppressed the migration and invasion of FLS, reduced the activity, expression and mRNA level of MMP-2, restrained the activation of FAK and reduced the expression of F-actin. Moreover, CA074Me decreased the phosphorylation of P38 MAPK and c-Jun N-terminal kinase (JNK) in FLS, while siCB treatment reduced the phosphorylation of P38 but not JNK. CB substantially contributes to the invasive phenotype of FLS that leads to joint destruction in RA. This proteinase may show promise as a therapeutic target in inflammatory arthritis.

Improvement of anaerobic digestion performance by continuous nitrogen removal with a membrane contactor treating a substrate rich in ammonia and sulfide

The effect of reduced ammonia levels on anaerobic digestion was investigated. Two reactors were fed with slaughterhouse waste, one with a hollow fiber membrane contractor for ammonia removal and one without. Different organic loading rates (OLR) and free ammonia and sulfide concentrations were investigated. In the reactor with the membrane contactor, the NH4-N concentration was reduced threefold. At a moderate OLR (3.1 kg chemical oxygen demand - COD/m(3)/d), this reactor performed significantly better than the reference reactor. At high OLR (4.2 kg COD/m(3)/d), the reference reactor almost stopped producing methane (0.01 Nl/gCOD). The membrane reactor also showed a stable process with a methane yield of 0.23 Nl/g COD was achieved. Both reactors had predominantly a hydrogenotrophic microbial consortium, however in the membrane reactor the genus Methanosaeta (acetoclastic) was also detected. In general, all relevant parameters and the methanogenic consortium indicated improved anaerobic digestion of the reactor with the membrane.

Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue-cage model in yellow cattle

The fluoroquinolone antimicrobial drug marbofloxacin was administered to yellow cattle intravenously and intramuscularly at a dose of 2 mg/kg of body weight in a two-period crossover study. The pharmacokinetic properties of marbofloxacin in serum, inflamed tissue-cage fluid (exudate), and noninflamed tissue-cage fluid (transudate) were studied by using a tissue-cage model. The in vitro and ex vivo activities of marbofloxacin in serum, exudate, and transudate against a pathogenic strain of Pasteurella multocida (P. multocida) were determined. Integration of in vivo pharmacokinetic data with the in vitro MIC provided mean values for the area under the curve (AUC)/MIC for serum, exudate, and transudate of 155.75, 153.00, and 138.88, respectively, after intravenous dosing and 160.50, 151.00, and 137.63, respectively, after intramuscular dosing. After intramuscular dosing, the maximum concentration/MIC ratios for serum, exudate, and transudate were 21.13, 9.13, and 8.38, respectively. The ex vivo growth inhibition data after intramuscular dosing were fitted to the inhibitory sigmoid Emax equation to provide the values of AUC/MIC required to produce bacteriostasis, bactericidal activity, and elimination of bacteria. The respective values for serum were 17.25, 31.29, and 109.62, and slightly lower values were obtained for transudate and exudate. It is proposed that these findings might be used with MIC50 or MIC90 data to provide a rational approach to the design of dosage schedules which optimize efficacy in respect of bacteriological as well as clinical cures.

Interleukin-25 promotes basic fibroblast growth factor expression by human endothelial cells through interaction with IL-17RB, but not IL-17RA

BACKGROUND

Unlike other IL-17 family members, the Th2-derived cytokine IL-25 (IL-17E) induces (promotes) Th2 responses. One or both of the two receptors for IL-25 (IL-17RA, IL-17RB) is expressed on inflammatory cells and tissue structural cells, suggesting that in addition to promoting Th2-type inflammation IL-25 may also act on structural cells at sites of Th2-type inflammation such as in the asthmatic bronchial mucosa to promote remodelling changes.

OBJECTIVE

Our previous studies showed elevated expression of IL-25 and IL-17RB immunoreactivity in asthmatic airways with co-localization of the latter to endothelial cells. We therefore hypothesized that IL-25 acts on endothelial cells through this receptor to induce production of the key angiogenic and remodelling cytokine basic fibroblast growth factor (bFGF).

METHODS

Polymerase chain reaction (PCR) immunocytochemistry/immunohistochemistry and ELISA were employed to detect expression of IL-17RB, IL-17RA and bFGF by human vascular endothelial cells (HUVEC) and immunoreactivity for IL-25 and bFGF in asthmatic bronchial biopsies. Receptor-blocking antibodies, PCR and an in vitro angiogenesis assay were used to investigate whether IL-25 acts on IL-17RB or IL-17RA to induce bFGF expression and angiogenesis. PCR was also employed to investigate the signalling pathways involved in IL-25-mediated bFGF expression.

RESULTS

HUVEC constitutively expressed IL-17RB, IL-17RA and bFGF. Production of the latter was further increased by IL-25, but attenuated after blockade of the IL-17RB, but not the IL-17RA receptor. Neutralization of endogenous VEGF and bFGF completely abrogated IL-25-induced angiogenesis which was also inhibited by blocking IL-17RB, but not IL-17RA. The PI3K-specific inhibitor LY294002 also completely attenuated IL-25-induced bFGF expression. Immunoreactivity for IL-25 and bFGF was elevated in the asthmatic bronchial mucosa and the expression of each correlated with the other.

CONCLUSIONS AND CLINICAL RELEVANCE

Our data support the hypothesis that IL-25 contributes to elevated bFGF in asthmatic airways by acting on the endothelial cell IL-17RB receptor through PI3K-signalling pathways. Targeting the pathways might benefit therapy of airways remodelling.

Treatment of mature landfill leachate by biofilters and Fenton oxidation

A series of processes by biofilter and Fenton oxidation to treat mature landfill leachate has been devised. At a hydraulic loading rate of 20 l m(-3)d(-1), a biofilter packed with aged refuse is found to remove 80% of chemical oxygen demand (COD), 89% of ammonia nitrogen and 96% of total phosphorus (TP). Particularly, TP levels dropped below 1 mg l(-1). The optimal condition for Fenton oxidation was selected to be an initial pH of 5, a dosage of 0.01 and 0.02 mol l(-1) of FeSO(4) and H(2)O(2), respectively, and a duration of 3h, where COD removal efficiency reaches 58.6%, and BOD(5)/COD ratio is raised from 0.05 to 0.20. Subsequent treatment by a biofilter packed with slag reduces COD, ammonia nitrogen levels to less than 100, 25 mg l(-1), respectively. A pilot scale experiment conducted in situ demonstrates that this series of processes exhibits a high efficiency in removing pollutants from mature landfill leachate and it is viable for application.

Expression of zinc-fingers and homeoboxes 2 in hepatocellular carcinogenesis: a tissue microarray and clinicopathological analysis

Zinc-fingers and homeoboxes 2 (ZHX2) is a novel transcriptional repressor. ZHX2 protein expression and its clinicopathological significance in hepatocellular carcinoma (HCC) remain largely unknown. The aim of this study was to analyze ZHX2 protein expression in a range of liver tissues obtained from cholangitis, cirrhosis, adjacent non-tumorous tissues, primary HCC tissues, and matched metastatic lesions by using Tissue microarray (TMA) technology and compare our findings with clinicopathological parameters. ZHX2 protein expression was detected only in HCC tissues. ZHX2 expression was associated with clinical stage of the disease. The rate of ZHX2 expression was approximately twice as high in stage III-IV (31.25%) compared with stage I-II (16.5%). These results demonstrated that ZHX2 protein may take part in hepatocellular carcinogenesis and HCC progression. In addition, ZHX2 expression in primary lesions with metastasis was significantly higher than without metastasis. ZHX2 expression in metastatic lesions (45.5%) was as approximately twice as higher than that in primary lesions (24.2%) from the same patient. According to these results, ZHX2 was associated with metastasis in HCC.

Identification of B cell epitopes at the C-terminus of latency-associated nuclear protein of the kaposi's sarcoma-associated herpesvirus

The latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV) plays a key role in the induction of cell transformation, maintenance of viral episome, and modulation of immune response in human. To identify the presence of B cell epitopes within C-terminus of LANA and to characterize the monoclonal antibodies (MAbs) against this protein, we expressed the C-terminal region at aa 794-1000 of LANA (pLANA-C) in Escherichia coli as a fusion protein. KSHV-positive human sera were able to recognize the recombinant LANA-C in the Western blot analysis and ELISA. Mapping of antigenic epitopes of pLANA-C by KSHV-positive human sera revealed two B cell antigenic epitopes located at aa 846-854 and aa 794-822. The MAb 3F11 recognized a region between at aa 840 to 846 of LANA and exhibited a strong and specific binding to both pLANA-C and native viral LANA. These findings showed that pLANA-C and MAb 3F11 could be used for the detection of KSHV antibodies in human sera and for the advanced study of biological functions of LANA.